Press Releases

Emergent BioSolutions Awarded Contract to Develop a Dry Formulation of NuThrax, a Next Generation Anthrax Vaccine

...

Read More

Emergent BioSolutions and MorphoSys Sign License Agreement to Co-Develop and Commercialize Prostate Cancer Drug Candidate ES414

...

Read More

U.S. Government Exercises Contract Options Valued at $18.9M for Emergent BioSolutions’ Vaccinia Immune Globulin Intravenous Program

...

Read More

Emergent BioSolutions Reports Financial Results for Second Quarter and First Six Months of 2014

...

Read More

Emergent BioSolutions Submits Biologics License Application to FDA for Anthrax Immune Globulin Intravenous (Human)

...

Read More

Emergent BioSolutions to Release Second Quarter 2014 Financial Results and Conduct a Conference Call on August 7, 2014

...

Read More

Emergent BioSolutions to Participate in June 2014 Investor Conferences

...

Read More

Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 22, 2014 at 9:00 AM Eastern; Webcast Will Be Available

...

Read More

Emergent BioSolutions Reports First Quarter 2014 Financial Results

...

Read More

Emergent BioSolutions to Release First Quarter 2014 Financial Results and Conduct a Conference Call on May 8, 2014

...

Read More

Emergent BioSolutions and FDA Finalize Comparability Protocols Enabling Manufacturing of BioThrax Consistency Lots in Building 55

...

Read More

Emergent BioSolutions Receives Orphan Drug Designation for BioThrax for Post-Exposure Prophylaxis of Anthrax Disease

...

Read More